Review 2025 – Dr. Richard Stone

FDA Approval for new AML drug/ Richard Stone, MD, Dana-Farber

Richard Stone, MD, provides opinion on whether all AML patients should be tested for FLT3 mutations

Cancer Research, Best of 2010s: Richard Stone, MD

Richard Stone, MD, elaborates on prognostic factors and the relationship to outcomes in AML

Richard Stone, MD, describes the landscape of mutations and targeted therapy in AML

2024 – Evening with the Experts – Dr. Richard Stone